C12N 2760/18161
Methods of inactivation or attenuation
C12N2760/18161 (Methods of inactivation or attenuation) appears on 10 US grants and 16 published applications in this corpus.
Search patents in C12N- Granted patents
- 10
- Published applications
- 16
- Assignees
- 19
- Inventors
- 49
- Latest grant
- 12 Aug 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1995 | 1 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 1 | 0 |
| 2005 | 0 | 1 |
| 2006 | 0 | 0 |
| 2007 | 2 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 3 |
| 2011 | 0 | 2 |
| 2012 | 1 | 0 |
| 2013 | 0 | 1 |
| 2014 | 0 | 0 |
| 2015 | 0 | 1 |
| 2016 | 1 | 0 |
| 2017 | 0 | 0 |
| 2018 | 0 | 1 |
| 2019 | 1 | 1 |
| 2020 | 1 | 0 |
| 2021 | 0 | 1 |
| 2022 | 1 | 1 |
| 2023 | 0 | 1 |
| 2024 | 0 | 0 |
| 2025 | 1 | 1 |
| 2026 | 0 | 2 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Recombinant HVT vectors expressing multiple antigens of avian pathogens and uses thereof12 Aug 2025US 12,385,068 B2Boehringer Ingelheim Animal Health USA Inc.
- Recombinant HVT vectors expressing multiple antigens of avian pathogens and uses thereof23 Aug 2022US 11,421,249 B2Boehringer Ingelheim Animal Health USA Inc.
- Recombinant HVT vectors expressing multiple antigens of avian pathogens and uses thereof3 Nov 2020US 10,822,620 B2Boehringer Ingelheim Animal Health USA Inc.
- Recombinant HVT vectors expressing multiple antigens of avian pathogens and uses thereof18 Jun 2019US 10,323,257 B2Boehringer Ingelheim Animal Health USA Inc.
- Newcastle disease virus and the use thereof as a vaccine21 Jun 2016US 9,370,563 B2Investigación Aplicada S.A. de C.V.
- Virus attenuation30 Apr 2026US 2026/0115273 A1University of Lancaster
- Newcastle Disease Virus with Improved Heat Resistance, and Newcastle Disease Virus Vaccine Comprising Same5 Mar 2026US 2026/0061047 A1Biopoa, Inc.
- Recombinant hvt vectors expressing multiple antigens of avian pathogens and uses thereof30 Oct 2025US 2025/0333766 A1Boehringer Ingelheim Animal Health USA Inc.
- Recombinant hvt vectors expressing multiple antigens of avian pathogens and uses thereof8 Jun 2023US 2023/0175017 A1Boehringer Ingelheim Animal Health USA Inc.
- Engineered newcastle disease virus vector and uses thereof15 Dec 2022US 2022/0396809 A1University of Guelph
Most cited
By later US patents
- Embryonal vaccine against Newcastle disease10US 5,427,791 ARegents of the University of Minnesota · 1995
- Production of novel Newcastle disease virus strains from cDNAs and improved live attenuated Newcastle disease vaccines7US 7,244,558 B1The United States of America, as represented by the Secretary, Department of Health and Human Services · 2007
- Recombinant HVT vectors expressing multiple antigens of avian pathogens and uses thereof6US 10,323,257 B2Boehringer Ingelheim Animal Health USA Inc. · 2019
- Compositions and methods for treatment of cancer5US 7,223,389 B2Theravir Management L.P. · 2007
- Recombinant HVT vectors expressing multiple antigens of avian pathogens and uses thereof3US 10,822,620 B2Boehringer Ingelheim Animal Health USA Inc. · 2020